Milestone Pharmaceuticals Inc. (MIST)
| Market Cap | 123.23M |
| Revenue (ttm) | 1.50M |
| Net Income (ttm) | -62.10M |
| Shares Out | 36.68M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 167,358 |
| Open | 3.48 |
| Previous Close | 3.49 |
| Day's Range | 3.23 - 3.48 |
| 52-Week Range | 3.10 - 9.85 |
| Beta | 1.99 |
| Analysts | Buy |
| Price Target | 15.50 (+361.31%) |
| Earnings Date | Mar 23, 2023 |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophyla... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for MIST stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 361.31% from the latest price.
News
Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia
- Both the NODE-303 and RAPID-extension studies are complete - Following FDA feedback, Etripamil NDA is on-track for submission in the third quarter of 2023 - Potential to be the first fast-acting,...
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Feb. 28, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ca...
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
The heavy selling pressure might have exhausted for Milestone Pharmaceuticals (MIST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...
Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT
Conference call and webcast on Tuesday, December 6, 2022 at 1:00 p.m. ET MONTREAL and CHARLOTTE, N.C.
Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Nov. 22, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ca...
Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update
- Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint; safety and tolerability data from repeat dose administration consistent with prior studies utilizing singl...
Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022
Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p
Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022
MONTREAL and CHARLOTTE, N.C., Oct. 25, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ca...
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 Weeks
Milestone Pharmaceuticals (MIST) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ea...
Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to imp...
Milestone's stock jumps 25% on positive data for tachycardia treatment
Shares of Milestone Pharmaceuticals Inc. MIST, -5.14% gained 25.4% in premarket trading on Monday after the company said its experimental treatment for paroxysmal supraventricular tachycardia met the ...
Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia
─ Trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p
Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
MONTREAL and CHARLOTTE, N.C., Sept. 6, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ca...
Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update
-- Phase 3 RAPID study reached the target of 180 confirmed PSVT events treated with double-blind study medication required to initiate primary efficacy analysis; topline data readout for RAPID study r...
Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
MONTREAL and CHARLOTTE, N.C., June 2, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., May 27, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
MONTREAL and CHARLOTTE, N.C., May 17, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
- RAPID topline data readout remains on track for mid-second half 2022 - Results from NODE-302 study highlights etripamil safety and reduced need for ED interventions MONTREAL and CHARLOTT...
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
- Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention - - As in other studies, etripamil was well tolerated by patients - - Data to be featured durin...
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT
Cardiac Electrophysiology Key Opinion Leaders to include Bruce Stambler, MD and Sean Pokorney, MD Conference call and webcast on Thursday, April 21, 2022 at 1:00 p.m. ET MONTREAL and CHARLOTTE, N.C.
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update
- RAPID topline data readout expected mid-second half 2022 MONTREAL and CHARLOTTE, N.C., March 24, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company...
Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer
MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ca...
Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MONTREAL and CHARLOTTE, N.C., Jan. 4, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT
- Etripamil significantly decreased heart rate during SVT episodes and independent of conversion to SR – - HR changes occurred within 5 minutes and were sustained for 60 minutes – - Data presented at ...